It is well established that interferons (IFNs) are able to inhibit the growth of mammalian tumour cells in vitro and also of xenografted tumours in nude or immune-deprived mice (Pauker et al., 1962; Taylor-Papadimitriou, 1980; Balkwill et al., 1982) . A number of different types of IFN have been used in these experimental studies including human leucocyte or lymphoblastoid (a) IFN, fibroblast (fi) IFN and lymphocyte (immune) (y) IFN. Earlier preparations of IFNs depended upon the purification of very small amounts of material obtained from cells grown in culture (Stewart, 1974) , or from human blood (Cantell & Hirvonen, 1977) . More recently IFN-a has been produced on a large scale from bulk cell culture and recombinant DNA techniques have allowed large scale production of IFNs from cloned interferon genes in E. coli bacteria. These cloned IFNs show much higher degrees of purity than IFNs purified from mammalian cell cultures.
Although IFN-c has been shown in clinical trials to have some activity in lymphomas, breast cancer, melanoma and myeloma, there was no response in either non-small cell (Stoopler et al., 1980) or small cell (Jones et al., 1983) lung cancers. In view of the impending availability for clinical trial of recombinant IFN-y, and our continuing interest in lung cancer therapy, we decided to investigate the comparative effects of IFN-a and IFN-y on lung cancer cells in culture and the effect of IFN-y on the growth of xenograft tumours in nude mice.
Materials and methods

Interferons
Human lymphoblastoid IFN-a was supplied by Dr N. Finter (Wellcome). This highly purified IFN-oa mixture is produced from the Namalwa cell line of Burkitt lymphoma. Its sp. act. was 1.0 x 108 IU mg-I protein (prior to the addition of human serum albumin as stabiliser). Recombinant IFN-y was kindly supplied by Biogen S.A. (Geneva). Two batches were used with sp. act. of 2.6 and 3.75 x 107 IU mg-1 protein respectively.
IFNs were stored at -70°C in storage buffer containing human serum albumin. Diluted aliquots in PBS were also stored at -70°C and thawed immediately before addition to cell cultures or injection into mice. The only exceptions to this were for some experiments (stated in Results) where IFN solutions for daily administration were kept at 4°C for the duration of the experiment.
Cell lines and media A number of cell lines were initially studied in order to gain information on the range of responses to a given dose of the two types of IFN. BEN, MOR and POC are human squamous cell, adeno and small cell lung cancer lines respectively and were supplied by Dr M. Ellison, Ludwig Institute, Sutton; NCI-H69 is a human small cell lung cancer line supplied by Dr D. Carney, NCI-Navy Medical Oncology Branch; EMT6/Ca/VJAC and RIF-l are mouse mammary tumour and mouse sarcoma cell lines respectively; COR-L23 is a cell line derived from the pleural fluid of a patient with large cell lung cancer and which forms tumours in nude mice.
The mode of growth and the media used for each line are shown in Table I . All culture media and serum were supplied by Gibco Ltd. HITES medium Cell growth experiments Cells were grown in the appropriate medium in 25 CM2 tissue culture flasks (Falcon). Some of the cell lines grew as attached monolayers whilst others grew as floating aggregates (see Table I ). The required number of flasks was set up from a large single cell suspension and IFN added as appropriate. At various times afterwards, the growth medium was removed from the cells in a flask (monolayers) or after centrifugation of the contents of a flask transferred to a plastic centrifuge tube (floating aggregates). A solution of 0.4% trypsin and 0.2% versene in PBS was then used to prepare a single cell suspension by incubation at 37°C for 15min, and phase-contrast viable cells were counted using a haemocytometer. In some experiments, the growth medium was changed daily and fresh IFN added.
Multicellular tumour spheroids Both POC and COR-L23 can be grown as multicellular tumour ,spheroids under static conditions. Spheroids of POC were initiated by the inoculation of 106 cells into 75cm2 tissue culture flasks. Aggregation occurred rapidly and spheroids of 250 pm diameter were present by day 14. As COR-L23 cells normally grow in monolayer, it was necessary to base-coat 75 cm2 flasks with I% Difco noble agar in medium to prevent cell attachment (Twentyman, 1980) . Spheroids of 250p,m diameter were obtained by day 10 following inoculation of 5 x 105 cells per flask.
When the spheroids had reached a diameter of 250-400im, they were individually transferred to wells on 24 well tissue culture trays (Linbro) using a Pasteur pipette. Medium (1 ml) was added to each well and spheroids were then measured three times weekly using an inverted microscope and an image analysis system (Twentyman, 1982) . In some experiments, the effect of carrying out a daily medium change was studied.
Flow cytometry
After preparation of a single cell suspension as above, cells were suspended at 2 x I0O cell ml -in RPMI 1640 medium containing 10% foetal calf serum. Staining with a mixture of mithramycin and ethidium bromide was carried out and the fluorescence distribution measured by passing the cells through the Cambridge flow cytometer using an argon laser operating at 488 um (Watson, 1980) . Analysis of cell cycle distribution was carried out using the method of Watson et al. (1985) .
Mouse experiments
Nude mice (MF1 nu nu) were obtained from OLAC Ltd. and maintained in negative pressure isolators (Vickers Medical) before and during experiments. They were used in experiments at a weight of 20-30g. Solid tumours were grown by injecting 2-5 x 106 cells into the gastrocnemius muscle of the hind limb. Cells were obtained from a previous xenograft passage by sterile disaggregation of one or more tumours and preparation of a single cell suspension using 1 mg ml -1 bacterial neutral protease (Sigma, Type IX). The experiments described in this paper were all carried out using xenograft-passage 2-4 from the in vitro cell line. Tumour growth was assessed by measuring two leg diameters at right angles using a perspex gauge in association with a calibration curve of leg diameter versus tumour weight (Twentyman et al., 1979) . IFN-y administration was commenced when individual tumours reached 200-300mg and tumours were then measured twice weekly as was mouse body weight. The time for each individual tumour to attain 4 x its weight at the onset of treatment was then assessed. IFN-y was administered either by the i.p. or the s.c. route at a dose of 4 x 10 5 IU per mouse per day in a volume of 0.1 ml per mouse per day. It was diluted to the appropriate concentration in storage buffer or saline, aliquoted and refrozen prior to use. In some experiments, aliquots were thawed immediately before administration. In others, sufficient IFN for 2-3 days treatment was thawed and stored at 4°C. Appropriate solvent controls were included in all experiments.
Results
Effects of IFNs on cell growth In a series of initial experiments, the effect of IFNa and IFN-y at a dose of 103IUml-I on the growth of various cell types was studied. The data are shown in Table II Figure 1 . These data confirm the relative sensitivity of POC compared with NCI-H69 and also the greater effect of IFN-y compared with IFN-a. Growth curves (not shown) for COR-L23 confirmed this latter point. We also obtained dose-response data for IFN-a and for our 2 batches of IFN-y on POC and COR-L23. Data for COR-L23 are shown in Figure 2 . It may be seen that the 2 batches of IFN-y were of similar potency and the IFN-oa was less effective. A similar conclusion was drawn from the data for POC (not shown). On the basis of these data it was decided to concentrate attention in subsequent experiments upon the effects of IFN-y on POC and COR-L23.
More complete dose-response data for the effect of IFN-y on these cells are shown in Figure 3 . The curves for both cell lines fall rapidly between 0 and 500 IU ml-1 of IFN-y with little further effect with increasing dose.
We also carried out experiments to study the effect on cell growth of IFN-y replenished daily versus a single addition at the onset of the experiments. The data are shown in Table III . In (0) b8-12 spheroids per treatment group. In experiments A and B, data on individual spheroid diameters were not stored and hence s.e. not given.
In experiment C, figures in parentheses indicate 2 s.e. of the mean. aDose= 4 x 105 i.u. per mouse per day (equivalent to 1.6 x 107IUkg-1 day-' or 4.8 x 107IUm-2day-').
Values of time in days are geometric means of groups of n mice with 2 s.e. limits in parentheses. spheroid growth. A larger effect was seen in flasks with daily medium change and a small inhibition of spheroid growth was also observed. In experiment B, a single administration of IFN-y produced no inhibition (in fact a small increase) in cells per flask and also in spheroid growth. Again the daily medium change regime was rather more effective in both systems. In experiment C, results in flasks are similar to those of experiment A, whereas spheroid growth was suppressed more for single than for repeated administration of IFN. The two standard error limits on mean spheroid diameter values in experiment C, however, indicate that the differences are not statistically significant and the same almost certainly applies to the equivalent data for experiments A and B. It would appear, therefore, that major differences seen in cells per flask (experiments A and C) for repeated administration of IFN-y do not result in equally large suppression of spheroid growth. This may indicate a reduced sensitivity of cells in large 3-dimensional aggregates or a failure of IFN to penetrate into the spheroids.
Effect in vivo
The data from 4 experiments carried out using human lung cell lines grown as tumours in nude mice are shown in Table VI . There was no significant effect of IFN-y in any of the experiments. No weight loss was seen in any of the groups of mice, neither were there any other visible signs of toxicity with the exception of one death due to haematoma at the site of s.c. injection.
Discussion
The results presented in this paper indicate that both IFN-ax and IFN-y are able to cause a partial suppression of the growth of some human lung cancer cell lines. In a direct comparison at a dose of 103IU ml-1, the effect of IFN-y was generally greater than that of IFN-a on the two most sensitive lines (POC and COR-L23) and this comparison was confirmed over a wide range of doses. The effect of IFN-y was related to dose over the region -104i.u.ml-P but the major part of the effect occurred below a dose of 500IUml-'. The major effect of IFN-y on cell growth curves was greatest at early times with later growth becoming almost parallel to control. These data on cell sensitivity to IFN-a and IFN-y may be compared with data from the literature for the effect of IFN-a on other cell lines (reviewed by Stewart, 1979) . The Daudi line of human lymphoblastoid cells is particularly sensitive (Adams et al., 1975; Gewart et al., 1981) (i.e. effects seen at less than 10IUml-1) whereas others are resistant to several thousand units. Our lines POC and COR-L23 may therefore be regarded as of intermediate sensitivity whereas the lines showing little or no response to 103 IU mI-may be regarded as resistant.
Our flow cytometry studies did not reveal any major perturbations in the cell cycle distribution of cells growing in the presence of IFN-y. Although some workers have found that IFNs do not cause major perturbations in cell cycle distribution (Killander et al., 1976; Balkwill et al., 1978) , a very wide diversity of effects of IFNs on cell cycle kinetics and phase distribution have, however, been reported by others (Watenabe et al., 1978; Lundgren et al., 1979; Creasey et al., 1980; Lundblad & Lundgren, 1981; Roos et al., 1984) . In the study by Lundblad and Lundgren (1981) the effects of IFN-oa and IFN-f on a glioma cell line in exponential growth were studied using flow cytometry. The proportion of cells with DNA contents corresponding to the S phase of the cell cycle was markedly increased in IFN treated cells. The authors combined their flow cytometry data with data obtained using labelling techniques to conclude that IFN was causing cessation of DNA synthesis before normal replication was complete. A number of human haemopoietic cell lines and fresh leukaemic cells were studied by Roos et al. (1984) . They found that the main effect of IFN-cx was to cause a block in the Go-G1 phase of the cell cycle, although the Burkitt's lymphoma line, Namalwa, showed decreased progress through S without any Go/GI accumulation, thereby leading to an increased S phase fraction judged by flow cytometry. Our flow cytometry data are difficult to interpret in detail in the absence of labelling studies to measure the rate of DNA synthesis. Clearly, however, major perturbations in cell cycle distribution which have been reported by others do not occur in the POC cell line treated with IFN-y. The growth inhibiting effects occurring at the time when flow cytometry was performed must therefore be dependent upon change in the rate of progress of cells around the cycle rather than major blocking at a specific point.
The negative results for the effect of 4 x 105i.u. day-l of IFN-y on tumours growing in nude mice are disappointing. It has been shown by Balkwill et al. (1982) that IFN-ax is able to slow the growth of a human breast carcinoma xenograft if given in daily doses of 2 x 105IU to nude mice. The same total weekly dose (i.e. 1.4 x 106 IU) either as a single dose or as 3 doses per week was much less effective. These doses were chosen as being approximately equivalent to the doses (based on IU m -2) which are achievable in man. A similar dose regime for IFN-a was used by Clutterbuck et al. (1983) to treat immune-deprived mice bearing xenografts of human lung adenocarcinoma, melanoma or acute myeloid leukaemia. In these experiments, IFN administration was carried out daily from the day before tumour implant for 14 days. No effect was seen on the growth of any of the tumours. The conclusion reached by Balkwill et al. (1982) from their data was that the positive response observed was likely to be due to a direct effect on the human cells rather than a host effect upon the nude mice used. If this is so, it appears that the psotive response to IFN-y which we have observed for COR-L23 and POC cells in vitro does not directly predict for a similar response in xenografted tumours. It may be, however, that this negative result is due to pharmacokinetic reasons. No detectable anti-viral activity was detected in patients' serum following i.m. injection of partially pure IFN-y and non-glycosylated recombinant IFNy appeared to be poorly absorbed in the squirrel monkey after i.m. administration (Gutterman et al., 1984) . We were unable, however, to carry out repeated i.v. injections into nude mice and thus are unable to directly compare routes of administration.
It is far from clear to what extent clinical response to IFNs is dependent upon direct cytotoxicity or cytostasis in the tumour cell population. In addition, a detailed knowledge of the pharmacokinetics of IFN-y in both the mouse and in man will be necessary for a direct comparison of in vitro, in vivo and clinical results. The implications of our data for the likely effect of IFN-y in clinical trials of lung cancer therapy must therefore remain uncertain.
